A Phase 3 interventional study of Mavacamten and Placebo in Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 12 of the 14 other live ones, and was the 32nd registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in China
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom
Ages 18+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2014; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 500 is above the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 59 across the 17 interventional studies, 200 across the 15 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06146660Bristol-Myers SquibbA Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | 2026-11-30 |
| NCT07557498Bristol-Myers SquibbMavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US | 2026-12-14 |
| NCT07541833Bristol-Myers SquibbEffectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) | 2026-12-31 |
| NCT06551129Bristol-Myers SquibbReal-world Patient Reported Outcomes Among Patients Treated With Camzyos | 2026-12-31 |
| NCT07846059Bristol-Myers SquibbEvaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to evaluate the safety and efficacy of Mavacamten in adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
This study's planned enrollment of 500 is above the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Browse Cardiomyopathy, Hypertrophic studies →Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Compared within Cardiomyopathy, Hypertrophic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiomyopathies. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Mavacamten
Drug: Mavacamten · Other: Placebo
Specified dose on specified days
Specified dose on specified days
Change from baseline in Peak Oxygen Consumption (pVO2)
Time frame: At Week 48
Change from baseline in Kansas City Cardiomyopathy Questionnaire, 23-item (KCCQ-23 CSS)
Time frame: At Week 48
Change from Baseline in Composite Z-score of Cardiopulmonary Exercise Testing (CPET) Parameters (pVO₂ and Ventilatory Efficiency (VE/VCO₂) Slope)
Time frame: At Week 48
Change from baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)
Time frame: At Week 48
Number of participants with at least 1 class of New York Heart Association (NYHA) improvement from baseline
Time frame: At Week 48
Change from baseline in Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Shortness of Breath (SoB)
Time frame: At Week 48
No study locations are listed for this record.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Start is estimated for Dec 2026; primary completion for Jul 2029, 30 months later.
Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's planned 30 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →